Lisa Banket
Cofounding Partner/Publisher
Taren Grom
Cofounding Partner/Editor-in-Chief
Heather Hummel
Project Coordinator
Dan Limbach
Producer, Webcast Network
Denise Myshko
Managing Editor
Kim Ribbink
Features Editor
Robin Robinson
Senior Editor
Marah Walsh
Cofounding Partner/New Business Development

PharmaVOICE Editors' Blog

Tuesday, April 30, 2013

New Challenges for Global Clinical Trials: Managing Supply Logistics in an Expanding Clinical Trial Universe

fisher clinical trials white paper
Global clinical trials require appropriate communication
Download this free white paper now.

This white paper provides an overview of the New Challenges for Global Clinical Trials. The specific challenges discussed are the changing regulatory environment, customs requirements, infrastructure issues, data management, regional idosyncrasies, and differing quality standards.

Provided by: Fisher Clinical Services

white paper

Monday, April 29, 2013

Upcoming Webinar: Prevention of Persistent Atrial Fibrillation – the Next Frontier in Pharmacotherapy

Atrial Fibrillation
Register for this webinar today

Thursday – May 30, 2013 / 11:00 am – 12:00 pm EST – Free Attendance

Sponsored by avertAF

The webinar will introduce the unmet need and pharmaceutical opportunity for pharmacological prevention of persistent atrial fibrillation. Professor Camm will put our discoveries and plans against the backdrop of recent advances in management of atrial fibrillation. Our focus is to enable cost-effective industry development of the first generation of disease modifying agents that aim to prevent the more serious forms of atrial fibrillation.

Register today!

During the webinar, we’ll discuss:
  • Current treatment objectives in atrial fibrillation
  • Unmet need in management of AF
  • Research findings on the role of remodeling in development of AF
  • Research findings related to role of galectin-3 and other targets
  • avertAF research objectives and plan
  • avertAF model and benefits to participating companies
Key Takeaways:
  • Atrial fibrillation is a common and serious arrhythmia
  • Recent pharmaceutical focus has been on prevention of complications
  • Animal studies point to structural and electric remodeling as important processes
  • These processes appear to be galectin-3 mediated
  • Blocking the remodeling pathway can prevent AF
  • avertAF is an open industry initiative
  • avertAF aims to facilitate drug development for AF prevention
Who Should Attend - Managers and above in:
  • Cardiovascular drug research and development
  • Business development
  • Strategy
Expert Presenters:

Bertram Pitt, MD
Professor Emeritus
University of Michigan

John Camm, QHP, MD
BHF Professor of clinical cardiology
St George’s University, London, and Imperial University, UK

José Jalife, MD
Cyrus and Jane Farrehi Professor of Cardiovascular Research
University of Michigan

Pieter Muntendam, MD

Register today!

Full webinar info

Tuesday, April 23, 2013

Value of a Credential in the Medical Publications Profession

CMPP credential from ISMPP
Value of a CMPP Credential
In this episode, Stacy Simpson Logan talks about the value of obtaining a CMPP credential for employees and employers as well as the future of the CMPP program. CMPP stands for Certified Medical Publication Professional and is administered by ISMPP, the International Society for Medication Publication Professionals.

Thought Leader:
Stacy Simpson Logan, Chair, CMPP Board of Trustees President, Waterfall Consulting

Download Podcast

Download Podcast Transcript

See All PharmaVOICE Podcasts

See All PharmaVOICE White Papers

Friday, April 12, 2013

White Paper: Telehealth Solutions Enhance Health Outcomes and reduce Healthcare Costs

telehealthcare tunstall americas
White paper: Can we enhance health outcomes with telehealth?

Download this free white paper now.

This white paper provides an overview of what telehealth is, factors driving the healthcare industry to focus on increasing outcomes and reducing costs, how telehealth solutions can enhance health outcomes and reduce costs, benefits life science companies can expect from telehealth solutions, as well as results from two key studies of telehealth solutions.

Provided by: Tunstall Americas

Tunstall Americas

Tuesday, April 9, 2013

White Paper - Speaking Up for Speaker Programs

Ogilvy Healthworld Marketing Analytics & Consulting

Download this free white paper now.

Faced with increased regulation and limited access to physicians, pharmaceutical companies are using analytics to more strategically plan and invest in peer-to-peer programming. Here, Ogilvy Healthworld Marketing Analytics & Consulting investigates the key factors that result in increased prescribing behavior.

Provided by: Ogilvy CommonHealth Worldwide

White paper
Ogilvy Healthworld Marketing Analytics & Consulting

Friday, April 5, 2013

Transitioning Clinical Trial Patients to Commercial Supply via Managed Access Programs

Idis podcast and case study

This podcast describes how Managed Access Programs can continue treatment access for patients coming out of registration or other clinical trials who need to transition to commercial supply.

Thought Leaders:

Suzanne Gagnon, MD, Chief Medical Officer, Idis
Karen Searle PhD, Study Director, Neuroscience & General Medicine (NGM), Eisai Global Clinical Development
Michelle Gee, PhD, Director, Neuroscience & General Medicine (NGM), Eisai Global Clinical Development

Download Podcast

Download Podcast Transcript

Download related case study

See All PharmaVOICE Podcasts

See All PharmaVOICE White Papers

Continuing Access Post-Clinical Trial - Case Study

post-clinical access to therapies
Clinical phases through launch

Download this free case study now.

Idis designed and implemented a Managed Access Program that enabled trial participants to continue use of the drug prior to its commercial availability, taking resource burden away from the company. Read this case study for more information, including the results of the program.

Provided by: Idis

post-clinical trial access

Thursday, April 4, 2013

What Do Mick Jagger, Diabetes, Heart Disease, and Cancer Have in Common?

Snowfish Podcast
Mick Jagger Keeps Going Strong

In this episode, Ms. Hammond talks about our aging society and how the industry needs to address its therapies to reflect the differences in age groups, including the old, and the very old.

Thought Leader: Melissa Hammond MSN, GNP, Managing Director, Snowfish LLC

Download Podcast

Download Podcast Transcript

Download Related White Paper

See All PharmaVOICE Podcasts

See All PharmaVOICE White Papers

10 Questions on Developing and Marketing Therapies for the Aging Population

marketing therapies to the geriatric aging population
Marketing therapies for the aging population
Download this free white paper now.

This white paper will address the critical questions for the industry and suggest prospective approaches that the industry can leverage as progressive companies target the enormous global emerging market that is older adults.

Provided by: Snowfish

Melissa Hammond, MSN, GNP, Managing Director
Snowfish LLC